A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer-Reference-Cited by-同舟云学术

A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer

Published:2014-09 Issue:9 Volume:105 Page:1182-1188
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Lin Ying¹,Liu Jianlun²,Zhang Xiaohua³,Li Li⁴,Hu Rui⁵,Liu Jian⁶,Deng Yongchuan⁷,Chen Dedian⁸,Zhao Yangbing⁹,Sun Shengrong¹⁰,Ma Rong¹¹,Zhao Ying¹²,Liu Jinping¹³,Zhang Yang¹⁴,Wang Xijing¹⁵,Li Yafen¹⁶,He Pingqing¹⁷,Li Enxiao¹⁸,Xu Zheli¹⁹,Wu Yaqun²⁰,Tong Zhongsheng²¹,Wang Xiaojia²²,Huang Tao²³,Liang Zhongxiao²⁴,Wang Shui²⁵,Su Fengxi²⁶,Lu Yunfei²⁷,Zhang Helong²⁸,Feng Guosheng²⁴,Wang Shenming¹

Affiliation:

1. Department of Surgery Breast Disease Center The First Affiliated Hospital Sun Yat‐Sen University GuangzhouChina

2. Department of Breast Surgery Guangxi Tumor Institute and Hospital NanningChina

3. Department of Breast Surgery The First Affiliated Hospital of Wenzhou Medical College WenzhouChina

4. Department of Oncology First Affiliated Hospital of Dalian Medical University DalianChina

5. Department of Breast Surgery Sichuan Cancer Hospital ChengduChina

6. Department of Oncology Fujian Provincial Tumor Hospital FuzhouChina

7. Department of Breast Surgery Second Affiliated Hospital College of Medicine Zhejiang University HangzhouChina

8. Department of Breast Surgery Yunnan Tumor Hospital KunmingChina

9. Department of Breast Surgery West China Hospital Sichuan University ChengduChina

10. Department of Breast and Thyroid Surgery The People's Hospital of Wuhan University WuhanChina

11. Department of Breast Surgery QiLu Hospital of Shandong University JinanChina

12. Department of Breast Surgery The First Affiliated Hospital Shanxi Medical University TaiyuanChina

13. Department of Breast Surgery The People's Hospital of Sichuan Province ChengduChina

14. Department of Medical Oncology The Second Affiliated Hospital Dalian Medical University DalianChina

15. Department of Surgical Oncology The Second Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'anChina

16. Department of Breast Surgery Ruijin Hospital School of Medicine Shanghai Jiaotong University ShanghaiChina

17. Department of General Surgery Shanghai Sixth People′s Hospital ShanghaiChina

18. Department of Medical Oncology The First Affiliated Hospital School of Medicine Xi'an Jiaotong University Xi'anChina

19. Department of Breast and Thyroid Surgery China‐Japan Union Hospital of Jilin University ChangchunChina

20. Department of Breast and Thyroid Surgery Tongji Affiliated Hospital Tongji Medical College of Huazhong University of Science and Technology WuhanChina

21. Department of Breast Surgery Cancer Institute and Hospital Tianjin Medical University TianjinChina

22. Department of Oncology Zhejiang Cancer Hospital HangzhouChina

23. Department of Breast and Thyroid Surgery Xiehe Affiliated Hospital Tongji Medical College of Huazhong University of Science and Technology WuhanChina

24. Second Department of Internal Medicine The People's Hospital of Guangxi Zhuang Autonomous Region NanningChina

25. Department of General Surgery The People's Hospital of Jiangsu Province/The First Affiliated Hospital of Nanjing Medical University NanjingChina

26. Department of Breast Surgery The Second Affiliated Hospital Sun Yat‐sen University GuangzhouChina

27. Department of Intestine and Gland Surgery The First Affiliated Hospital Guangxi Medical University NanningChina

28. Department of Oncology Tangdu Hospital The Fourth Military Medical University/The Second Affiliated Hospital The Fourth Military Medical University Xi'an China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12474

Reference32 articles.

1. The changing global patterns of female breast cancer incidence and mortality

2. Report of incidence and mortality in China cancer registries, 2009;Chen W;Chin J Cancer Res,2013

3. Cancer incidence and mortality in China, 2007

4. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.Version 1.2006:NCCN 2006.

5. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of fatty liver and hepatic fibrosis associated with long-term use of tamoxifen or anastrozole may be overestimated in patients with breast cancer;2024-04-03

2. Comparison of effects of tamoxifen and Toremifene on hepatic function and serum lipids in breast cancer patients during adjuvant endocrine therapy;Anti-Cancer Drugs;2024-01-22

3. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance;Journal of Hepatology;2023-12

4. Unravelling the potential of selected phenolics against breast cancer targets: Molecular docking and molecular dynamics investigations;South African Journal of Botany;2023-11

5. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy;Nature Reviews Endocrinology;2023-10-02